The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aditya Arora & PACs

pdf

Kwality Pharmaceuticals Ltd.

16 Feb 2024

815.15

3.57%

SAST

Kwality Pharmaceuticals Ltd - 539997 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

BSE India

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aditya Arora & PACs

pdf

Kwality Pharmaceuticals Ltd.

06 Feb 2024

815.15

3.57%

Result

Kwality Pharmaceuticals Ltd - 539997 - Submission Of Unaudited Financial Results For The Quarter And Nine …

BSE India

Submission of Unaudited financial results for the quarter and nine months ended 31-12-2023

pdf

Kwality Pharmaceuticals Ltd.

06 Feb 2024

815.15

3.57%

Board Meeting

Kwality Pharmaceuticals Ltd - 539997 - Board Meeting Outcome for Unaudited Financial Results For The Quarter …

BSE India

Pursuant to Regulation 30 & 33 read with clause 4 (h) of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulation, 2015 ('Listing Regulations'), this is to inform you that Board of Directors in its meeting held today i.e., February 06, 2024, have inter-alia , considered and approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended 31st December, 2023 along with Limited Review Report issued by Statutory Auditors of the Company. A copy of the same is enclosed herewith.

pdf

No results found

Is Kwality Pharmaceuticals Ltd. worth buying?

56 Votes:

Buy 71.43%

Sell 16.07%

Hold 12.5%